论文信息 - A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. - 字舞流文

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones | Yulei N. Wang | J. Bendell | J. Infante | Y. Wang | L. Camacho | K. Moore | J. Infante | G. Abbadessa | M. Saleh | C. Kurkjian | S. Pant | B. Schwartz | S. Jones | J. Kazakin | Y. Chen | M. Saleh